US/UK/Canada

Share

Contacts

  • Cyxone AB
    Hyllie Boulevard 34, 215 32 Malmö, Sweden
    +46 708882172
    +46 708882172
    https://cyxone.com/en/

    • Quotes

    We are happy to announce the positive study outcomes, an instrumental part of the preparations for the Phase 2 study in RA patients set to start late next year. Equally, we are eagerly looking forward to the imminent initiation of our clinical study of Rabeximod in Covid-19 patients. Combined with the new patent applications recently filed, with potential to substantially prolong market exclusivity, and with a stockpile of drug substance enabling further clinical studies beyond those currently in the pipeline, we stand with a strong foothold in future partnering negotiations. All in all, Cyxone is well-positioned for the development of safe and innovative treatments toward serious immune system disorders.
    Tara Heitner, CEO, Cyxone
    After thorough evaluation, we were able to decide upon this CRO as our partner of choice for these preclinical studies. The selected CRO has an excellent reputation and we got a great impression of their quality and professionalism from the start. We now look forward to take the next step in the development program for our Phase II candidate Rabeximod.
    Malin Berthold, Head of Project Management at Cyxone
    This market maker is now being implemented to increase liquidity of our stock, which has sometimes been low. We look very favorably on this support measure, which is primarily done to benefit our shareholders through reduced trading risks.
    Kjell G. Stenberg, CEO of Cyxone
    The acquisition of Rabeximod is the most important milestone since Cyxone was founded. I have been following Rabeximod's development in OxyPharma for a long time and believe that this investment is very beneficial for our shareholders. We have in a short time been able to build a world-class autoimmune product portfolio, which has permeated the discussions we have had with different stakeholders regarding the financing of Rabeximod's phase IIb study. This is why we are now taking the opportunity to complete the payment and hope to return soon to our shareholders with more positive news regarding Rabeximod.
    Kjell G. Stenberg, CEO of Cyxone
    Pick a time period -
    Tags ( Active)

    First Berlin Equity Research publishes independent analysis of Cyxone

    Cyxone (publ.), a clinical stage biotech company developing first-in-class drugs for diseases of the immune system, announces today that the research company First Berlin Equity Research has published an independent analysis report of Cyxone.The independent analysis covers the first nine months of 2020 and a pipeline update. In the analysis, which was published on 17 December 2020, First Berlin reviewed the company’s potential with an expected but continued positive outcome. The report in English can be read in its entirety on the Cyxone’s website. Contact Tara Heitner, CEOTel:

    Correction: Previous press release had an incorrect MAR reference.

    First Berlin Equity Research publishes independent analysis of Cyxone Cyxone (publ), a Swedish biotech in autoimmune diseases, announces today that the internationally renowned research company First Berlin Equity Research has published an independent analysis report of Cyxone.The independent analysis covers the first quarter of 2020 and was published on 26 June 2020, where First Berlin reviewed the company’s potential with an expected but continued positive outcome. The report in English can be read in its entirety on the Cyxone’s website. ContactTara Heitner, CEOTel: +46 70

    First Berlin Equity Research publishes independent analysis of Cyxone

    Cyxone (publ), a Swedish biotech in autoimmune diseases, announces today that the internationally renowned research company First Berlin Equity Research has published an independent analysis report of Cyxone.The independent analysis covers the first quarter of 2020 and was published on 26 June 2020, where First Berlin reviewed the company’s potential with an expected but continued positive outcome. The report in English can be read in its entirety on the Cyxone’s website. ContactTara Heitner, CEOTel: +46 70 781 88 08Email: tara.heitner@cyxone.com Adelgatan 21211 22 Malmö,

    Mangold Insight publishes company analysis of Cyxone

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that an analysis of the company has been published by Mangold Insight.The company analysis was published on Tuesday, September 10, 2019. Mangold Insight has taken into account the company's potential for the next 12 months. The report can be read in its entirety in Swedish only on the company's website. ContactCyxone AB (publ)Kjell G. Stenberg, CEOTel: +46 (0) 723 816 168Email: kjell.g.stenberg@cyxone.comAdelgatan 21211 22 Malmö, Sweden About CyxoneCyxone AB is a clinical stage biotech company with

    First Berlin Equity Research publishes independent analysis of Cyxone

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the internationally renowned research company First Berlin Equity Research has published an independent analysis report of Cyxone.The independent analysis covers the first half-year of 2019 and was published on Monday, December 04, 2018, where First Berlin Equity Research reviewed the company's potential with an expected but continued positive outcome. The report in English can be read in its entirety on the company's website. ContactCyxone AB (publ)Kjell G. Stenberg, CEOTel: +46 (0) 723 816 168Email:

    First Berlin Equity Research publishes updated independent analysis of Cyxone

    Cyxone (publ) announced today that the internationally renowned research company First Berlin Equity Research has published an updated independent analysis report of Cyxone.The updated analysis was published on Monday, July 01, 2019, where First Berlin Equity Research has further taken into account the company's potential with a continued positive outcome. The report in English can be read in its entirety on the company's website. ContactCyxone AB (publ)Kjell G. Stenberg, CEOTel: +46 (0) 723 816 168Email: kjell.g.stenberg@cyxone.comAdelgatan 21211 22 MalmöSweden About

    First Berlin Equity Research publishes updated independent analysis of Cyxone

    Cyxone (publ) announced today that the internationally renowned research company First Berlin Equity Research has published an updated independent analysis report of Cyxone.The updated analysis was published on Monday, December 04, 2018, where First Berlin Equity Research has further taken into account the company's potential with a continued positive outcome. The report in English can be read in its entirety on the company's website. ContactCyxone AB (publ)Kjell G. Stenberg, CEOTel: +46 (0) 723 816 168Email: kjell.g.stenberg@cyxone.comAdelgatan 21221 22 MalmöSwedenwww.

    First Berlin Equity Research publishes independent analysis of Cyxone

    Cyxone (publ) announced today that the internationally renowned research house First Berlin Equity Research has published an independent analysis report of the company.The analysis was published on Tuesday, October 30, 2018, where First Berlin Equity Research has taken into account the company's potential with a positive outcome. The report in English can be read in its entirety on the company's website. ContactCyxone AB (publ)Kjell G. Stenberg, CEOTel: +46 (0) 723 816 168Email: kjell.g.stenberg@cyxone.comAdelgatan 21221 22 MalmöSwedenwww.cyxone.com About Cyxone

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media